Australian melanoma rates take the silver – and that's good news
31 March 2016
The average risk of melanoma in Australia may have peaked in 2005 while New Zealand's rates of melanoma have risen to be the highest globally. However, Australia's burden of melanoma might stay very high over the next 15 years as the population ages. MIA Research Director Professor Mann explains.
A new study by QIMR Berghofer Medical Research Institute, one of MIA’s research affiliates, has examined melanoma rates in six different countries and used current trends to predict how they will change in coming years.
The latest data from cancer registries are from 2011. In the five years prior to that, 50 cases of melanoma occurred per 100,000 people in New Zealand while in Australia the rates fell slightly from our world-leading position in 2002-06, to 48 cases per 100,000 in 2011. Researchers predict a peak incidence of about 51 in New Zealand by 2016-2017; while in Australia rates should continue to edge down from a peak of about 49 in 2005.
Why is this happening?
The main clue is that rates of melanoma in young and middle aged Australian adults peaked in the early 2000s. This is good news because it shows that our awareness, prevention and sun protection work, especially with children in recent decades, is reaping benefits that will clearly continue in decades to come. In New Zealand the same impact has been seen in the young, but the rise of melanoma in older people has been stronger and harder to stop.
The down side of these results is that the sun exposure “banked” by people who grew up in the 1920s-1950s is still being converted into skin cancer and melanoma, especially as these generations are living longer. The total number of cases of melanoma will probably stay steady in Australia until the 2030s, but in New Zealand it is predicted to grow another 25% over 2011 levels.
So we have all been doing a pretty good job of holding this epidemic at bay, but we need to work harder with Australians over 50 (like me!). These age groups missed out on sun smart campaigns as youngsters and UV radiation has already damaged their skin badly. However, we know that our risk of melanoma and other forms of skin cancer is driven by the total dose of UV that we get throughout our life, not just when we were young. So, just as it is never too late to stop smoking, every year of good sun protection helps undo the damage done before.
Dedicated and increased prevention efforts to reduce unnecessary UV exposure remains our key weapon to fight melanoma in the future. It would be great to show by 2030 that these predictions of melanoma rates in older Australians for the 2020s were too pessimistic.
Two publications co-edited by MIA Co-Medical Director Professor Richard Scolyer are now available to healthcare professionals. They aim to provide assistance in the care and management of patients with skin cancer, including melanoma.
Melanoma Institute Australia has introduced a new educational program to teach teenagers about the dangers of melanoma and the importance of sun safety.
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.